Teva is working to sell off its women’s health unit to churn up cash and pay down debt, and it may have some takers.
The assets have sparked interest from U.S. healthcare and consumer companies Church & Dwight Co. and Cooper Cos., Bloomberg reported, and they’re weighing bids for part of Teva’s women’s health lineup.
Final bids on the portfolio, which could bring in $2 billion or more, could come as early as later this week, the report said, with the embattled generics giant selling the unit either intact or divided up between U.S. and European assets.
While Church & Dwight and Cooper have their eye on the U.S. products, they may have to vie with European and Asian companies and private equity outfits, Bloomberg noted. India’s Intas Pharmaceuticals and French buyout firm Astorg Parnters could get involved, and the portfolio has reportedly attracted buyout firms such as CVC Capital Parnters, TPG Capital, Apollo Global Management and more.
For Teva, any money it can gin up through a women’s health sale—or sales—will be more than welcome. The company, suffering under a mound of debt it racked up through its disastrous, $40 billion-plus Allergan generics buy, has warned that it may not be able to meet its debt covenant agreements.
And women’s health isn’t the only unit on the block. The Israeli pharma is also working to sell off its European oncology and pain business, as well as Iceland-based unit Medis. Sources have told Bloomberg some respiratory treatments could be up for grabs, too.
By Carly Helfand
Source: Fierce Pharma
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.
